Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.78 USD
-0.04 (-4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.79 +0.01 (1.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALGS 0.78 -0.04(-4.40%)
Will ALGS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALGS
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ALGS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
Aligos Therapeutics mourns passing of advisor Stephen Harrison
Aligos Therapeutics to present data on ALG-097558 at ESCMID
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024